Complete Response to Trastuzumab-Based Chemotherapy in a Patient with Human Epidermal Growth Factor Receptor-2-Positive Metastatic Salivary Duct Carcinoma ex Pleomorphic Adenoma

Publisher： Karger

E-ISSN： 1662-6575|6|3|450-455

ISSN： 1662-6575

Source： Case Reports in Oncology, Vol.6, Iss.3, 2013-09, pp. : 450-455

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Durable Response of Human Epidermal Growth Factor Receptor-2-Positive Gastric Adenosquamous Carcinoma to Trastuzumab-Based Chemotherapy

By  

Case Reports in Oncology, Vol. 7, Iss. 1, 2014-03 ,pp. : 210-216

Karger

Access to resources Recommend Favorite

Patient‐reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T‐DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2–positive locally advanced or metastatic breast cancer

By  

CANCER, Vol. 120, Iss. 5, 2014-03 ,pp. : 642-651

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rapid Intracranial Response to Osimertinib in a Patient with Epidermal Growth Factor Receptor T790M-Positive Adenocarcinoma of the Lung

By  

Oncology Research and Treatment, Vol. 39, Iss. 7-8, 2016-06 ,pp. : 461-463

Karger

Access to resources Recommend Favorite

Human Epidermal Growth Factor Receptor 2-Positive Duodenal Adenocarcinoma: A Case Report and Review of the Literature

By  

Case Reports in Oncology, Vol. 8, Iss. 2, 2015-07 ,pp. : 285-289

Karger

Access to resources Recommend Favorite

Impact of clinicopathological characteristics on the efficacy of neoadjuvant therapy in patients with human epidermal growth factor receptor‐2‐positive breast cancer

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 142, Iss. 4, 2018-02 ,pp. : 844-853

John Wiley & Sons Inc

Access to resources Recommend Favorite